NCT06904196View on ClinicalTrials.gov

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
COMBINATION_PRODUCT

Lenvatinib plus SIRT

Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD will be started at 3-7 days after the first SIRT.

DRUG

Lenvatinib

Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD.

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER